$Replimune(REPL.US)$ NEWS Replimune Group, Inc. announced positive interim results from the ARTACUS Phase 1/2 clinical trial evaluating RP1 monotherapy for skin cancers in transplant patients, showing a 34.8% overall response rate with good durability. The treatment was well-tolerated and resulted in immune activation.
Replimune股票讨论
Replimune 在 2024 年美国临床肿瘤学会 (ASCO) 年会上公布了来自 RP1 和 RP2 临床项目的积极数据
Replimune在2024年ASCO年会上公布了其RP1和RP2临床项目的积极数据。IGNYTE试验显示,在抗PD-1失效黑色素瘤中,RP1加nivolumab的总缓解率(ORR)为32.7%,反应持续超过六个月,中位持续时间超过36个月。RP2,既是单一疗法,又是伴随疗法...
” 前20名的持股量:86.71%
” 季度环比变化**:-9.29%
顶级持股:
$因塞特(INCY.US)$
$百济神州(BGNE.US)$
$阿卡迪亚(ACAD.US)$
$Madrigal Pharmaceuticals(MDGL.US)$
$Rhythm Pharmaceuticals(RYTM.US)$
$Revolution Medicines(RVMD.US)$
$Kymera Therapeutics(KYMR.US)$
$AbCellera Biologics(ABCL.US)$
$Bicycle Therapeutics(BCYC.US)$
$Edgewise Therapeutics(EWTX.US)$
$Immunocore(IMCR.US)$
$Kodiak Sciences(KOD.US)$
$Roivant Sciences(ROIV.US)$
...
NEWS
Replimune Group, Inc. announced positive interim results from the ARTACUS Phase 1/2 clinical trial evaluating RP1 monotherapy for skin cancers in transplant patients, showing a 34.8% overall response rate with good durability. The treatment was well-tolerated and resulted in immune activation.
我之所以对溶瘤病毒感兴趣,是因为病毒本身是一种药物,同时,病毒可以成为其他药物的载体。目前,其他药物不具有这种双重特性,我们有责任充分利用这一功能。 $Replimune(REPL.US)$ $Candel Therapeutics(CADL.US)$
暂无评论